Endomyocardial Biopsy Market By Product Type (Biopsy Forceps or Bioptomes, Guiding Catheters and Sheaths, Imaging-Guided Sampling Systems, Supporting Procedural Accessories); By Application (Post-Heart Transplant Rejection Monitoring, Myocarditis Diagnosis, Infiltrative Cardiomyopathies, Unexplained Heart Failure Evaluation, Other Cardiac Tissue Analysis Applications); By End User (Transplant Hospitals, Specialty Cardiac Centers, Academic and Research Institutions, Advanced Diagnostic Centers); By Geography, Segment Revenue Estimation and Forecast, 2026–2032

Endomyocardial Biopsy Market: Transplant Volumes, Diagnostic Yield, and Non-Invasive Testing Reshape Commercial Demand

The Global Endomyocardial Biopsy Market was valued at USD 308.64 million in 2025 and is projected to reach USD 490.77 million by 2032, expanding at a CAGR of 6.85% during the forecast period.

 

The market is driven by repeat heart-transplant surveillance and the targeted diagnosis of inflammatory and infiltrative heart disease. Revenue also comes from disposable biopsy forceps, vascular-access products, cardiac pathology, immunohistochemistry, and molecular testing.

 

Demand is concentrated in transplant hospitals and advanced cardiovascular centers, not across the wider hospital market. Each procedure depends on catheterization-laboratory capacity, imaging guidance, tissue-sampling tools, pathology processing, specialist interpretation, and post-procedure monitoring. The biopsy instrument itself accounts for only part of the value created during a biopsy episode.

 

Market growth is therefore best measured through procedure volumes, transplant-center activity, diagnostic conversion, pathology requirements, and reimbursement rather than overall cardiovascular-disease prevalence.

 

The market also has a recurring consumables component. Each procedure may require a new forceps set, vascular-access components, specimen-handling materials, pathology reagents, and specialist laboratory services. This broadens the revenue base beyond device sales. However, because procedures are concentrated in a limited number of high-volume centers, hospital purchasing groups retain significant negotiating power. Suppliers must provide dependable distribution, consistent product availability, and evidence that their products reduce inadequate samples and repeat procedures.

 

Heart Transplantation Creates the Largest Recurring Procedure Pool

Post-transplant rejection surveillance remains the most predictable source of endomyocardial biopsy demand. Clinical literature describes transplant-rejection monitoring as the most common global use of EMB, although no unified international procedure registry verifies the frequently cited estimate that transplant recipients account for more than 85% of all procedures. The commercial conclusion remains valid: transplant programs generate the largest repeat-use customer base because one recipient may undergo several biopsies during the first year.

Older U.S. market estimates were based on approximately 3,500 to 4,000 heart transplants annually and traditional schedules requiring 10 to 12 surveillance biopsies during the first year. That combination produced a theoretical baseline of roughly 35,000 to 48,000 procedures annually.

Current official data indicate that the transplant pool is larger. The United States performed 4,636 heart transplants in 2024, compared with 2,554 in 2013, an increase of approximately 81.5%. The number of centers conducting at least one adult or pediatric heart transplant also increased from 126 to 146.

Applying an intensive 10-to-12-biopsy schedule to the 2024 transplant total would produce a theoretical first-year pool of approximately 46,000 to 56,000 U.S. procedures. Historical programs did use schedules approaching 10 to 14 biopsies during the first year, particularly when molecular surveillance was unavailable.

Contemporary utilization is lower. Claims data covering 8,170 commercially insured and Medicare heart-transplant patients found a median of 4.6 to 6.8 biopsies during the first post-transplant year. Applying this observed range to the 4,636 U.S. transplants completed in 2024 indicates a more conservative potential pool of approximately 21,000 to 31,500 first-year biopsy episodes.

The difference between the two estimates reflects changes in clinical practice rather than a statistical error. Traditional schedules created 10 or more procedures per recipient, while current programs increasingly use donor-derived cell-free DNA, gene-expression profiling, echocardiography, and clinical risk factors to reduce routine biopsies in stable patients.

Global transplant activity creates a similarly important demand base. Earlier estimates of 8,000 to 9,000 annual heart transplants implied approximately 80,000 to 108,000 first-year procedures under intensive 10-to-12-biopsy schedules. The Global Observatory on Donation and Transplantation reported 10,287 heart transplants worldwide in 2024, meaning the theoretical pool would now exceed 100,000 procedures if traditional schedules were applied consistently.

Actual global volume is likely lower because biopsy protocols, reimbursement, molecular-testing access, patient risk, and center resources vary considerably. The market is therefore influenced by two opposing forces: transplant growth expands the eligible patient pool, while biomarker-guided monitoring lowers the average number of biopsies performed on low-risk recipients.

 

Biopsy Episode Costs Exceed Instrument Revenue

The financial value of endomyocardial biopsy extends well beyond the bioptome. A complete episode can include hospital facility charges, physician services, catheterization, imaging, pathology, laboratory analysis, recovery monitoring, and complication management.

A four-year U.S. claims analysis found that the median paid amount for an outpatient biopsy in 2019 was USD 7,918 for commercially insured patients and USD 2,980 for Medicare patients. Commercial payments increased by almost 25% between 2016 and 2019, while complication-related spending moved the effective median closer to USD 10,000 per episode.

A Milliman analysis of 2023 and 2024 commercial claims estimated an average outpatient episode cost of nearly USD 8,000 for transplant patients aged 15 and older and approximately USD 15,000 for those younger than 15. Pediatric cases can require anesthesia, additional monitoring, and greater specialist involvement. The study was commissioned by CareDx, a supplier of non-invasive transplant-monitoring tests, which should be considered when interpreting its commercial conclusions.

These costs do not represent forceps revenue. They show why hospitals, payers, device manufacturers, pathology laboratories, and molecular-diagnostic companies compete for value within the same rejection-monitoring pathway. They also explain why payers and transplant centers are interested in reducing routine biopsies that have a low probability of identifying clinically significant rejection.

 

Diagnostic Yield Depends on Patient Selection and Laboratory Depth

Outside transplantation, EMB is used when identifying the cause of myocardial disease could change treatment. Relevant indications include unexplained heart failure, suspected myocarditis, giant-cell myocarditis, cardiac sarcoidosis eosinophilic disease, amyloidosis, storage disorders, and selected cardiomyopathies.

A 2025 cohort of 681 cases reported a specific pathological diagnosis in 230, producing an overall diagnostic yield of 33.8%. Yield reached 34.4% in native hearts and 29.4% in transplanted hearts. Higher procedure volume therefore does not automatically create more actionable diagnoses when referral and patient-selection criteria are weak.

A European analysis of 8,085 patients with unexplained heart failure reported that comprehensive biopsy evaluation produced a definitive diagnosis and specific treatment in 79% of cases. It identified inflammatory heart disease in 42% of patients, cardiac storage disease in 7.6%, acute myocarditis in 4.4%, and treatment-relevant viral infections in 25%.

The 33.8% and 79% figures reflect different patient populations, diagnostic methods, and definitions of a useful result. The European assessment combined histopathology, immunohistochemistry, and molecular testing and included cases in which findings guided therapy. The comparison shows that market value increasingly comes from the complete diagnostic workflow rather than tissue collection alone.

Demand therefore extends to specialized cardiac-pathology laboratories, viral genome testing, immune-cell analysis, amyloid typing, and other molecular services. Hospitals without experienced cardiac pathologists may depend on centralized laboratories, creating service revenue beyond the catheterization laboratory.

 

Myocarditis Supports Selective Rather Than Routine Growth

Cardiac magnetic resonance imaging has reduced the need for biopsy in uncomplicated cases, but imaging cannot always determine the inflammatory subtype, viral status, or cellular pattern required to guide treatment.

Biopsy retains the greatest value in severe, unexplained, rapidly progressive, or treatment-resistant disease where distinguishing giant-cell myocarditis, eosinophilic myocarditis, sarcoidosis, viral disease, or immune-mediated inflammation could alter therapy. It also remains important when non-invasive findings are inconclusive.

Commercial growth in myocarditis will therefore depend on better referral and targeting rather than routine biopsy of every suspected case. Imaging guidance and electroanatomical mapping can direct sampling toward abnormal tissue, potentially increasing diagnostic yield and reducing repeat procedures caused by inadequate specimens.

 

Disposable Forceps Form the Core Product Segment

Biopsy forceps, or bioptomes, are the central procedural product. Commercial differentiation depends on obtaining an adequate specimen with limited tissue compression, maintaining predictable jaw movement, passing through the selected access route, and supporting right- or left-ventricular sampling.

Argon Medical Devices is one of the most visible dedicated suppliers through its JAWZ endomyocardial biopsy forceps. The disposable portfolio uses dual cutting heads manufactured from a proprietary alloy and is designed to produce clean tissue margins with less crushed artefact. The range includes different lengths, coatings, diameters, and straight, pre-curved, or maxi-curved configurations.

Cordis supplies dedicated 5.5F and 7F endomyocardial biopsy forceps and compatible long sheaths. The company reports tissue-sample volumes of 2.46 mm³ and 5.20 mm³, respectively, with configurations supporting jugular or femoral access. Its combination of biopsy tools and vascular-access products strengthens its position in hospitals seeking fewer suppliers across the procedure.

Scholten Surgical Instruments markets the disposable Novatome bioptome and has experience with reusable instruments. Fehling Instruments has U.S. clearance for forceps intended to obtain right- or left-ventricular specimens through arterial or venous access. Cook Medical maintains a broad biopsy, wire-guide, introducer, and vascular-access portfolio, although the availability of specific endomyocardial products can differ by geography.

Terumo Corporation and Merit Medical Systems are more accurately classified as adjacent procedural suppliers than dedicated EMB forceps manufacturers. Terumo supplies guidewires, diagnostic catheters, guiding catheters, and other coronary-access products used across cardiac catheterization procedures. Merit Medical offers sheath introducers, diagnostic guidewires, cardiology catheters, hemostasis valves, and related cath-lab tools. Their commercial exposure comes from the access and support components surrounding tissue sampling rather than the biopsy forceps alone.

Boston Scientific has a large interventional-cardiology business and manufactures biopsy forceps for other clinical applications. However, its currently published Radial Jaw portfolio is designed for endoscopic tissue collection, and available product information does not establish it as a current dedicated endomyocardial-bioptome supplier. It should therefore be treated as an adjacent medical-device company unless a market assessment identifies a region-specific cardiac biopsy product.

Single-use forceps are gaining importance because they reduce sterilization requirements, preserve consistent jaw sharpness, and limit cross-contamination concerns. Reusable devices may lower acquisition costs across multiple procedures, but cleaning validation, wear, repair, and inconsistent cutting performance can reduce their economic advantage.

 

Accessories and Pathology Expand Revenue per Procedure

Each biopsy supports demand for introducer sheaths, guide catheters, guidewires, vascular-access kits, imaging supplies, sterile procedure packs, specimen containers, stains, antibodies, and laboratory reagents.

Merit Medical and Terumo can participate in this surrounding revenue pool through sheath introducers, diagnostic wires, catheters, fluid-management products, and other catheterization-laboratory accessories. Cordis has a more integrated position because it supplies both dedicated biopsy forceps and long vascular sheaths.

CMS states that endomyocardial biopsy code 93505 should be billed as one unit regardless of the number of specimens or myocardial sites sampled. Hospitals therefore receive no additional procedure-code payment from collecting more tissue fragments during the same encounter.

Sample quality has direct commercial importance. An inadequate specimen can require additional pathology work, produce an inconclusive result, or lead to another invasive procedure. Suppliers able to demonstrate consistent tissue quality can compete on total procedural value rather than forceps price alone.

 

Non-Invasive Testing Is the Main Market Restraint

Gene-expression profiling and donor-derived cell-free DNA testing are changing post-transplant surveillance. These blood tests help identify recipients with a low probability of rejection and allow centers to reserve biopsy for abnormal biomarkers, graft dysfunction, donor-specific antibodies, or other clinical concerns.

A contemporary study included 2,240 heart-transplant recipients from 59 U.S. centers and evaluated 24,768 biopsies alongside 8,851 paired donor-derived cell-free DNA samples. Antibody-mediated rejection was found in 2.6% of biopsies overall, but the rate ranged from 1.1% in patients with normal graft function and no donor-specific antibodies to 20.4% in patients with graft dysfunction and known antibodies.

These findings support risk-based biopsy rather than uniform surveillance. Low-risk patients may avoid an invasive procedure, while high-risk patients can be directed toward tissue confirmation when diagnostic yield is considerably higher.

CareDx reported approximately 50,300 testing-service volumes in the third quarter of 2025, an increase of 13% year over year. Testing-services revenue reached USD 72.2 million, although these figures include kidney, heart, and lung products and do not represent heart-testing revenue alone.

Many centers now use molecular tests alongside biopsy rather than fully replacing it. The likely market direction is fewer low-yield procedures in stable recipients but continued tissue confirmation when rejection is suspected, molecular findings conflict, or graft function deteriorates.

 

North America Leads Monetizable Demand

North America combines a large transplant population, established procedure coding, commercial insurance payments, advanced catheterization infrastructure, and growing molecular-surveillance adoption. The United States’ 4,636 heart transplants and 146 active transplant centers in 2024 create a concentrated customer base for forceps suppliers, access-device manufacturers, and cardiac-pathology laboratories.

Europe remains important because of its transplant programs, specialist cardiomyopathy centers, and use of immunohistochemical and molecular biopsy analysis. Spain performed 347 heart transplants in 2024, approximately 7% more than in 2023. Donation after circulatory death accounted for 29.1% of the country’s heart transplants, showing how organ-recovery innovation can expand the recipient pool and future rejection-surveillance demand.

Asia-Pacific demand is concentrated in major academic and transplant hospitals. Growth depends on transplant capacity, specialist interventional cardiologists, cardiac-pathology access, reimbursement, and molecular-testing availability.

 

Competitive Outlook

Market expansion will depend on rising transplant volumes, better selection of native-heart patients, and the ability of biopsy to provide information unavailable from non-invasive tests.

Dedicated forceps suppliers such as Argon Medical Devices and Cordis compete through tissue quality, jaw design, disposable availability, access configurations, and transplant-center contracts. Broader cardiovascular companies, including Terumo and Merit Medical, participate through access and catheterization products. Pathology providers compete on turnaround time and the breadth of histological, immunohistochemical, and molecular analysis.

Non-invasive diagnostic companies will continue working to reduce routine surveillance procedures and redirect biopsy toward high-risk cases. This shift may reduce the number of biopsies performed per stable transplant patient but increase the diagnostic value of each remaining procedure.

The market is therefore moving away from a purely schedule-driven model. Future revenue will increasingly depend on transplant growth, risk-based procedure selection, disposable instrument penetration, sample quality, and the depth of pathology services attached to each biopsy episode.

 

Endomyocardial Biopsy Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 308.64 Million
Revenue Forecast in 2032	USD 490.77 Million
Overall Growth Rate	CAGR of 6.85% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Biopsy Forceps (Bioptomes), Guiding Catheters and Sheaths, Imaging-Guided Sampling Systems, Supporting Procedural Accessories
By Application	Post-Heart Transplant Rejection Monitoring, Myocarditis Diagnosis, Infiltrative Cardiomyopathies, Unexplained Heart Failure Evaluation, Other Cardiac Tissue Analysis Applications
By End User	Transplant Hospitals, Specialty Cardiac Centers, Academic and Research Institutions, Advanced Diagnostic Centers
By Geography	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Increasing heart transplantation volumes, growing need for rejection surveillance, rising adoption of disposable biopsy devices, expansion of cardiac pathology and molecular testing, demand for targeted diagnosis of inflammatory and infiltrative heart diseases
Customization Option	Available upon request